CareLit · DOI-Nachweis · Das Gesundheitswesen
Erythropoietin-induced Treatment Costs in Patients Suffering from Renal Anemia – A Comparison between Biosimilar and Originator Drugs
DOI 10.1055/s-0033-1361111
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHörbrand, F.; Rottenkolber, D.; Fischaleck, J.; Hasford, J.
ZeitschriftDas Gesundheitswesen
Ausgabe11/2014
Jahrgang / SeitenJg. 76 · S. e79 bis e84
Kernaussage aus der Literatur
Abstract-Vorschau
Renal anemia is a serious concern for morbidity and lower quality-of-life of patients suffering from chronic kidney disease resulting in a high economic burden when administering erythropoiesis-stimulating agents (ESAs). The aim of this study was to estimate erythropoietin-induced treatment costs in patients suffering from renal anemia undergoing dialysis treated with originator or biosimilar drugs. A retrospective…
Zitieren
Zitierempfehlung
Hörbrand, F.; Rottenkolber, D.; Fischaleck, J.; Hasford, J (2014) Erythropoietin-induced Treatment Costs in Patients Suffering from Renal Anemia – A Comparison between Biosimilar and Originator Drugs. Das Gesundheitswesen, 76 (11), e79 bis e84. https://doi.org/10.1055/s-0033-1361111
Mit CareLit weiterarbeiten